TScan Therapeutics (TCRX.US) issued 30 million U.S. dollars of pre-financing warrants.
Biotechnology company TScan Therapeutics (TCRX.US) announced on Thursday that they will sell approximately $30 million in pre-financing warrants.
Biotechnology company TScan Therapeutics (TCRX.US) announced on Thursday that it will sell approximately $30 million in pre-financing warrants, which can be used to purchase a total of up to 7.5 million shares with voting rights at a price of $4.00 per share. As of the time of writing, the company's stock was up 22.68% in pre-market trading, at $3.57.
TCRX has entered into a securities purchase agreement with Lynx1 Capital Management and Lynx1 Consulting's investment fund.
Each pre-financing warrant can be exercised to purchase one share with voting rights of common stock at an exercise price of $0.0001 per share.
The financing is expected to be completed around December 27th.
Related Articles
NOIZ GROUP (08163) issues a profit warning, expecting a net loss of approximately HK$9 million to HK$15 million for the fiscal year 2025.
STAR GROUP ASIA (01560) issues profit warning. It is expected that the company's equity holders' losses for the year 2025 will narrow by approximately 299.3 million Hong Kong dollars compared to the previous year.
ESUN HOLDINGS (00571) announced its interim results, with a profit attributable to shareholders of HK$9.333 million, turning losses into gains year-on-year.
NOIZ GROUP (08163) issues a profit warning, expecting a net loss of approximately HK$9 million to HK$15 million for the fiscal year 2025.
STAR GROUP ASIA (01560) issues profit warning. It is expected that the company's equity holders' losses for the year 2025 will narrow by approximately 299.3 million Hong Kong dollars compared to the previous year.
ESUN HOLDINGS (00571) announced its interim results, with a profit attributable to shareholders of HK$9.333 million, turning losses into gains year-on-year.
